Effect of magnesium in the treatment of gestational diabetes

Effects of magnesium supplementation on metabolic status and pregnancy outcomes in women with gestational diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201503055623N39

Enrollment

Registered

2015-03-10

Start date

2014-01-11

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes. Diabetes mellitus in pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Magnesium tablet as magnesium oxide, 250 mg, daily for 6 weeks orally. Intervention 2: Control group: Placebo tablet, daily for 6 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Pregnant women aged 18-40 years Pregnant women diagnosed with GDM 24-28 weeks' gestation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.	—

Secondary

Measure	Time frame
Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Newborns' weight. Timepoint: The first 24 h after birth. Method of measurement: Scale.;Newborn length. Timepoint: The first 24 h after birth. Method of measurement: Newborn head circumference.;Newborn head circumference. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.;Polyhydramnios. Timepoint: Post-intervention. Method of measurement: Sonography.	—

Measure

Time frame

Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Newborns' weight. Timepoint: The first 24 h after birth. Method of measurement: Scale.;Newborn length. Timepoint: The first 24 h after birth. Method of measurement: Newborn head circumference.;Newborn head circumference. Timepoint: The first 24 h after birth. Method of measurement: Girth measuring tape.;Polyhydramnios. Timepoint: Post-intervention. Method of measurement: Sonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5562 0608

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 17, 2026